| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | quetiapine (Seroquel XL®) |
| Formulation | 50 mg, 150 mg, 200 mg, 300 mg and 400 mg prolonged-release tablet |
| Reference number | 647 |
| Indication | Add-on treatment of major depressive episodes in patients with Major Depressive Disorder who have had sub-optimal response to antidepressant monotherapy |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/06/2010 |